The FDA has granted approval to Zepbound, a popular weight loss medication, for the treatment of moderate to severe obstructive sleep apnea. This marks the first FDA-approved prescription drug specifically for adults with obstructive sleep apnea.
The FDA has approved Zepbound , a popular weight loss drug, for the treatment of moderate-to-severe obstructive sleep apnea . According to drugmaker Eli Lilly, it’s the first and only FDA -approved prescription medication for adults with obstructive sleep apnea . It’s also FDA -approved to treat obesity.
Obstructive sleep apnea is a breathing disorder characterized by complete or partial collapses of the upper airway during sleep, which can lead to pauses in breathing (apnea) or shallow breathing (hypopnea). That can cause a potential decrease in oxygen saturation and wake someone from sleep. Symptoms include:Sleep apnea can also prevent weight loss. FDA approval for Zepbound to treat sleep apnea was based on three clinical trials, Eli Lilly said, which found Zepbound was five times more effective than a placebo in reducing breathing disruptions in adults, both on and off PAP therapy. According to Eli Lilly, after one year, 42% of adults on Zepbound and 50% of adults on Zepbound with PAP therapy experienced remission or mild, non-symptomatic obstructive sleep apnea, compared to 16% and 14% of people who took the placebo, respectively.Adults on Zepbound also lost an average of 45 pounds. That increased to 50 pounds for adults on PAP therapy who took Zepbound. People who took the placebo lost an average of 4 pounds and 6 pounds, respectively. The latest popular weight loss drugs are known as GLP-1 receptor agonists because they mimic a hormone in the body known as glucagon-like peptide 1. Mounjaro and Zepbound are versions of a drug called tirzepatide. Zepbound, Mounjaro, Wegovy and Ozempic work in similar ways to reduce appetite. But Zepbound and Mounjaro are what’s called 'dual-agonist' drugs while Wegovy and Ozempic are what’s known as 'single-agonist' drug
Weight Loss Sleep Apnea Drug Approval FDA Zepbound
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance coverage for the treatment.
Read more »
FDA approves weight loss drug Zepbound for sleep apneaBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Read more »
FDA Approves Weight-Loss Drug Zepbound for Sleep ApneaIt’s the first prescription drug to be approved to treat the condition.
Read more »
FDA approves weight loss drug Zepbound to treat obstructive sleep apneaThe FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.
Read more »
FDA approves weight loss drug Zepbound to treat obstructive sleep apneaThe FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.
Read more »
FDA approves Zepbound for obstructive sleep apneaZepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep apnea.
Read more »